Halozyme Q3 2016 Earnings Call November 7

Halozyme Therapeutics presents Q3 2016 earnings results and updates on its HALO-301 Phase 3 trial investigating PEGPH20 combined with ABRAXANE and gemcitabine for metastatic pancreatic cancer. The randomized, double-blind study enrolls approximately 420 patients across 200 sites in 20 countries with progression-free survival and overall survival as primary endpoints.